Employed (n = 431) | Not employed (n = 276) | Total (n = 707) | |
---|---|---|---|
Age, years | 43.6 (9.4)* | 47.4 (10.9) | 45.1 (10.2) |
Gender, male, n (%) | 321 (74.5)† | 133 (48.2) | 454 (64.2) |
Race, White, n (%) | 386 (89.6) | 238 (86.2) | 624 (88.3) |
Body mass index | 27.7 (5.2) | 28.3 (5.9) | 28.0 (5.5) |
Psoriasis disease duration, years | 18.0 (10.2) | 19.1 (12.6) | 18.4 (11.2) |
PsA disease duration, years | 6.7 (6.7) | 7.5 (7.5) | 7.0 (7.0) |
Physician Psoriasis Assessment (scale: 0–5; higher scores = worse psoriasis) | 3.6 (0.6)* | 3.7 (0.7) | 3.6 (0.7) |
PASI (scale: 0–72; higher scores = worse psoriasis) | 18.5 (9.5)* | 21.4 (11.1) | 19.6 (10.3) |
BSA affected, % | 28.7 (21.4)* | 34.7 (23.6) | 31.0 (22.5) |
PGA of arthritis (scale: 0–100; higher scores = worse arthritis) | 48.9 (20.4)* | 53.2 (21.5) | 50.6 (20.9) |
Swollen joints (0–68) | 11.4 (13.9)* | 14.5 (16.8) | 12.6 (15.2) |
Tender joints (0–72) | 17.6 (16.8)* | 22.0 (19.1) | 19.4 (17.9) |
DLQI, total (scale: 0–30; higher scores = worse dermatology-related quality of life) | 11.6 (7.3)* | 13.8 (7.7) | 12.5 (7.3) |
EQ-5D Utility (scale: 0–1; higher scores = better quality of life), mean | 0.55 (0.28)* | 0.38 (0.35) | 0.48 (0.32) |
EQ-5D VAS (scale: 1–100; higher scores = better health), mean | 58.0 (20.7)* | 51.9 (20.6) | 55.6 (20.9) |
HAQ DI (scale: 0–3; higher scores = more disability), mean | 0.72 (0.59)* | 1.20 (0.75) | 0.91 (0.69) |